- Home
- EXC vs ARGX Comparison
EXC vs ARGX Comparison
Compare EXC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXC
- ARGX
- Stock Information
- Founded
- EXC 1999
- ARGX 2008
- Country
- EXC United States
- ARGX Netherlands
- Employees
- EXC N/A
- ARGX N/A
- Industry
- EXC Power Generation
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXC Utilities
- ARGX Health Care
- Exchange
- EXC Nasdaq
- ARGX Nasdaq
- Market Cap
- EXC 37.0B
- ARGX 40.4B
- IPO Year
- EXC N/A
- ARGX 2017
- Fundamental
- Price
- EXC $43.39
- ARGX $644.48
- Analyst Decision
- EXC Buy
- ARGX Strong Buy
- Analyst Count
- EXC 8
- ARGX 20
- Target Price
- EXC $43.38
- ARGX $653.11
- AVG Volume (30 Days)
- EXC 7.4M
- ARGX 225.0K
- Earning Date
- EXC 02-12-2025
- ARGX 02-27-2025
- Dividend Yield
- EXC 3.67%
- ARGX N/A
- EPS Growth
- EXC 4.82
- ARGX N/A
- EPS
- EXC 2.45
- ARGX N/A
- Revenue
- EXC $23,028,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- EXC $3.23
- ARGX $73.18
- Revenue Next Year
- EXC $2.64
- ARGX $55.26
- P/E Ratio
- EXC $17.82
- ARGX N/A
- Revenue Growth
- EXC 5.99
- ARGX 85.56
- 52 Week Low
- EXC $34.01
- ARGX $349.86
- 52 Week High
- EXC $43.69
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- EXC 75.64
- ARGX 49.33
- Support Level
- EXC $42.21
- ARGX $637.15
- Resistance Level
- EXC $43.45
- ARGX $652.23
- Average True Range (ATR)
- EXC 0.81
- ARGX 12.63
- MACD
- EXC 0.11
- ARGX -1.94
- Stochastic Oscillator
- EXC 92.56
- ARGX 30.64
About EXC Exelon Corporation
Exelon serves approximately 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware, and Washington, D.C.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.